Key takeaways
- Intuitive reported second-quarter 2026 revenue of $2.89 billion, up 19%, and said da Vinci procedures grew about 15% and its installed base reached 11,710 systems.
- Medtronic’s Hugo system received FDA clearance for urologic procedures on December 3, 2025; the first US surgery was at Cleveland Clinic in February, and the FDA cleared a further instrument for Hugo on September 16, 2026.
- Intuitive estimates tariffs will reduce its 2026 gross margin by about 1% of revenue, and it booked a $28 million benefit from refunds of earlier tariffs.
- Intuitive had not published third-quarter results at the time of our check; the company’s published full-year outlook is 13.5% to 15.5% da Vinci procedure growth.
Robotic-assisted surgery is the most mature part of medical robotics, and the two leading names are on different stages of the same curve: Intuitive, whose da Vinci systems have been sold for decades, and Medtronic, whose Hugo system has only recently reached US hospitals. This report uses company results and regulatory announcements, and labels our own analysis.
Intuitive’s second quarter
In its July 16 results, Intuitive said worldwide procedures, da Vinci and Ion combined, grew about 16% from a year earlier, with da Vinci procedures up about 15% and Ion procedures, which use its lung-biopsy platform, up about 36%. It placed 468 da Vinci systems in the quarter versus 395 a year earlier, of which 246 were the newer da Vinci 5. The installed base reached 11,710 da Vinci systems on June 30, up 12% from 10,488, plus 1,096 Ion systems. Revenue was $2.89 billion, up 19%, instruments and accessories revenue (the recurring consumables tied to procedures) was $1.73 billion, and GAAP net income attributable to the company was $818 million. Of the systems placed, 254 were under operating lease arrangements, 131 of them usage-based.
The company guided to full-year da Vinci procedure growth of roughly 13.5% to 15.5%, and said it expected to be closer to the midpoint. The company has not reported third-quarter numbers yet, so any change in US procedure growth is not yet visible in its disclosures.
Financial scale
For the first six months of 2026, Intuitive reported revenue of $5.66 billion versus $4.69 billion a year earlier, and ended June with $8.63 billion in cash and investments. The company also said it completed the acquisition of its da Vinci and Ion distribution businesses in Italy, Spain and Portugal, moving those markets from a distributor model to direct sales. Those figures describe a company with substantial resources to fund new products, which is the benchmark any new entrant is compared against.
Tariffs
Intuitive said its gross margin outlook includes an estimated tariff effect of 1.0% of revenue, and that most of its instruments are made in Mexico and its endoscopes mainly in Germany. It also recorded a net-of-tax benefit of $28 million, or $0.08 per share, from refunds of tariffs paid in earlier periods under the International Emergency Economic Powers Act. The company cautioned that additional tariffs “could be material.”
Medtronic’s Hugo reaches the US
Medtronic announced on December 3, 2025 that the FDA cleared the Hugo robotic-assisted surgery system for urologic procedures including prostatectomy, nephrectomy and cystectomy. On February 17, 2026 it reported the first US surgery with Hugo, performed at Cleveland Clinic. On September 16, 2026 it announced FDA clearance of the LigaSure RAS Maryland instrument for use with Hugo. We reviewed these announcements in search excerpts rather than in full, and we did not find a published timeline for clearance in other specialties such as gynecology or general surgery.
What the numbers do not show
Company results measure sales, not clinical outcomes. Whether robotic surgery improves outcomes relative to laparoscopic or open surgery varies by procedure, and the documents above do not address it. Cost is the other open question: Intuitive’s growing use of leasing and usage-based arrangements shifts the hospital’s cost from a one-time purchase to per-procedure payments, and hospital budgets, rather than technology, are one of the limits the company itself lists among its risk factors, along with capital-spending delays and staffing constraints. Intuitive’s risk disclosures also name competition from other robotic surgical systems, including domestic competitors in some markets such as China, and delays in obtaining new product clearances. Patients and hospitals comparing systems will therefore be weighing training, instrument availability and service contracts as much as the robots themselves.
Why it matters
Our analysis: the entry of a second major US-cleared system gives hospitals a negotiating alternative for the first time in a market long dominated by one supplier. Whether Hugo takes meaningful share will depend on how many specialties it is cleared for and on pricing, neither of which is yet public. For Boston-area readers, the region’s hospitals and device companies are part of this market; see our coverage of AI in biology and lab discovery and of the safety platforms being built for AI agents for the software side of medical automation.
Sources
- Intuitive: Second quarter 2026 earnings release (July 16, 2026)
- SEC filing: Intuitive Surgical Form 10-Q for the quarter ended June 30, 2026
- Medtronic: FDA clearance of Hugo for urologic procedures (Dec. 3, 2025)
- Medtronic: First US surgery with Hugo at Cleveland Clinic (Feb. 17, 2026)
- Medtronic: FDA clearance for LigaSure RAS Maryland instrument on Hugo (Sept. 16, 2026)
More technology coverage: Tech and AI business news.